← Leaderboards
Judith H Merritt
Glycobia, Inc.
$1,834,429
Attributed
$1,834,429
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2014–15$2M$1.5M$1M$500K$0
'14
'15
Funding mix
By agency
NIH$1,834,429 · 2
By mechanism
R44$1,834,429 · 2
Top collaborators
No co-investigators on record.
Most similar at Glycobia, Inc.
Same institution · by research overlap
- Adam Charles Fisher$2,961,327
- Brian D. Green$1,216,474
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroPeptidesEngineeringHuman BodyLeadMarketingDrug CandidateDrug TargetingGenerationsHalf-LifeCommercializationBenchmarkingAnimalsCost EffectiveAnabolismCollaborationsDrug KineticsBioreactorsBacteriaEscherichia ColiGlycopeptidesGlycosylationAnimal ModelPerformance
Grant awards (3)
Glycoconjugate therapeutic peptides for improved treatment of human diseases$636,906
R44 · FY2015 · GM · contact PI
Engineering Escherichia coli for sialylation of therapeutic proteins$595,302
R44 · FY2015 · GM · contact PI
Engineering Escherichia coli for sialylation of therapeutic proteins$602,221
R44 · FY2014 · GM · contact PI